Loading…
FUROSEMIDE is a brand name for Furosemide (also known as Frusemide). The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Furosemide 10 mg/ml Solution for Injection is used for the management of fluid retention and for the management of mild to moderate hypertension, either alone or as an adjunct.
Verbatim from this product's MHRA label. Tap a section to expand.
General:
The dose used must be the lowest that is sufficient to achieve the desired effect. g. in impaired intestinal absorption) or if a rapid effect is required. If intravenous therapy is used, it is recommended that transfer to oral therapy be carried out as soon as possible.
Intravenous furosemide must always be injected or infused slowly, a rate of 4 mg per minute must not be exceeded. The diuretic effect of Furosemide 10 mg/ml Solution for Injection is proportional to the dosage. 5 mg per minute is not exceeded.
Intramuscular administration must be restricted to exceptional cases where neither oral nor intravenous administration are feasible. It must be noted that intramuscular injection is not suitable for the treatment of acute conditions such as pulmonary oedema.
To achieve optimum efficacy and suppress counter-regulation, a continuous furosemide infusion is generally to be preferred to repeated bolus injections. Where continuous furosemide infusion is not feasible for follow-up treatment after one or several acute bolus doses, a follow-up regimen with low doses given at short intervals (approx.
4 hours) is to be preferred to a regimen with higher bolus doses at longer intervals. Doses of 20 to 50 mg intramuscularly or intravenously may be given initially. If larger doses are required, they should be given increasing by 20 mg increments and not given more often than every two hours.
If doses greater than 50 mg are required it is recommended that they be given by slow intravenous infusion. The recommended maximum daily dose of furosemide administration is 1500 mg. 5 mg/kg body weight daily up to a maximum total daily dose of 20 mg.
Elderly:
In the elderly furosemide is generally eliminated more slowly. Dosage should be titrated until the required response is achieved.
The frequencies are derived from literature data referring to studies where furosemide is used in a total of 1387 patients, at any dose and in any indication. When the frequency category for the same ADR was different, the highest frequency category was selected.
01%; Not known (cannot be estimated from available data). Metabolism and nutrition disorders Very Common: electrolyte disturbances (including symptomatic) dehydration and hypovolaemia, especially in elderly patients. Blood creatinine increased, blood triglyceride increased.
Common: hyponatremia, hypochloremia, hypokalaemia, blood cholesterol increased. Blood uric acid increased and attacks of gout, urine volume increased. Uncommon: glucose tolerance impaired. Not known: hypocalcemia, hypomagnesemia, blood urea increased, metabolic alkalosis, Pseudo-Bartter syndrome.
Vascular Disorders Very Common:
Hypotension including orthostatic hypotension. Rare: vasculitis. 5) Gastrointestinal disorders Uncommon: nausea, Rare: vomiting, diarrhoea. Very Rare: pancreatitis acute Hepatobiliary disorders Very Rare: cholestasis, transaminases increased Ear and labyrinth disorders Uncommon: hearing disorders.
Cases of deafness, sometimes irreversible have been reported after oral or IV administration of furosemide. Very Rare: tinnitus. Uncommon: deafness (sometimes irreversible) Skin and subcutaneous tissue disorders Uncommon: pruritus, urticaria, rashes, dermatitis bullous, erythema multiforme, pemphigoid, dermatitis exfoliative, purpura, photosensitivity reaction Not known: Stevens-Johnson syndrome, toxic epidermal necrolysis, AGEP (acute generalized exanthematous pustulosis) and DRESS (Drug Rash with Eosinophilia and Systemic Symptoms).
Not Known: acute generalised exanthematous pustulosis (AGEP), lichenoid reactions. Immune system disorders Rare: severe anaphylactic or anaphylactoid reactions. Not known: exacerbation or activation of systemic lupus erythematosus Nervous system disorders Rare: paraesthesiae.
Too vigorous diuresis may cause orthostatic hypotension or acute hypotensive episodes. Where indicated, steps should be taken to correct hypotension or hypovolaemia before commencing therapy. Regular monitoring of serum sodium, potassium and creatinine is generally recommended during furosemide therapy; particularly close monitoring is required in patients at high risk of developing electrolyte imbalances or in case of significant additional fluid loss.
Hypovolaemia or dehydration as well as any significant electrolyte and acid- base disturbances must be corrected. This may require temporary discontinuation of furosemide. Urinary output must be secured. In patients with a partial obstruction of urinary outflow increased production of urine may provoke or aggravate complaints.
These patients require careful monitoring. Patients with partial obstruction of urinary outflow, for example patients with prostatic hypertrophy or impairment of micturition have an increased risk of developing acute retention and require careful monitoring.
Particularly careful monitoring is necessary in: • patients with hypotension. • patients who are at risk from a pronounced fall in blood pressure. • patients with latent or manifest diabetes. Furosemide may necessitate adjustment of control by hypoglycaemic agents in cases of diabetes mellitus.
g. associated with nephritic syndrome (the effect of furosemide may be weakened and its ototoxicity potentiated). Cautious dose titration is required. • premature infants (possible development nephrocalcinosis nephrolithiasis; renal function must be monitored and renal ultrasonography performed).
The use of diuretics is considered to be unsafe in acute porphyria therefore caution should be exercised. Concomitant use with risperidone In risperidone placebo controlled trials in elderly patients with dementia, a higher incidence of mortality was observed in patients treated with furosemide plus risperidone when compared to patients treated with risperidone alone or furosemide alone.
Patients with hypovolaemia or dehydration, anuria or renal failure with anuria not responding to furosemide, renal failure as a result of poisoning by nephrotoxic or hepatotoxic agents or renal failure associated with hepatic coma, severe hypokalaemia, severe hyponatraemia, pre-comatose and comatose states associated with hepatic encephalopathy and breast feeding women.
Hypersensitivity to furosemide or any of the excipients of Furosemide 10 mg / ml Solution for Injection. Patients allergic to sulphonamides may show cross- sensitivity to furosemide.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Furosemide in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Common: hepatic encephalopathy in patients with hepatocellular insufficiency. 3) Not Known: Dizziness, fainting or loss of consciousness (caused by symptomatic hypotension or by other causes), headache. Blood and the lymphatic system disorders Common: haemoconcentration.
Uncommon: thrombocytopenia Rare: leucopoenia, eosinophilia Very rare: agranulocytosis, aplastic anaemia, haemolytic anaemia. Congenital and familiar/genetic disorders Not known: increased risk of persistence of patent ductus arteriosus when furosemide is administered to premature infants oduring the first weeks of life.
General disorders and administration site conditions Not known: following intramuscular injection, local reactions such as pain. Rare: fever. 3) Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorization of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Cautions should be exercised and the risks and benefits of this combination or co-treatment should be considered prior to the decision to use. Dehydration should be avoided. The possibility exists of exacerbation or activation of systemic lupus erythematosus hence caution should be taken when administering frusemide to patients with a history of SLE.
Symptomatic hypotension leading to dizziness, fainting or loss of consciousness can occur in patients treated with furosemide, particularly in the elderly, patients on other medications which can cause hypotension and patients with other medical conditions that are risks for hypotension.
This medicinal product contains less than 1 mmol sodium (= 23 mg) per dose, that is to say essentially ‘sodium- free’.